RxDoctor Payments Data

Khashana Blake, MD

Family Medicine · Winston Salem, NCNPI 1356543490

Payments from drug & device makers

$653in general payments, 2019–2025

Across 13 payments — averaging $50.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$127
  • Otsuka America Pharmaceutical, Inc.$125
  • AstraZeneca$121
  • Mylan Specialty L.p.$120
  • Avanir Pharmaceuticals, Inc.$89
  • Lilly USA, LLC$71

What the payments were for

  • Food & beverage$653100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$653 in reported general payments places this provider in the 60th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$143,914
Medicare patients
454
Services billed
1,244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban719$260,891
XareltoRivaroxaban184$73,714
AustedoDeutetrabenazine13$66,687
TrulicityDulaglutide61$60,105
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$49,304
MyrbetriqMirabegron162$47,285
JardianceEmpagliflozin94$35,433
EntrestoSacubitril/Valsartan86$34,224
TradjentaLinagliptin70$33,359
FarxigaDapagliflozin Propanediol68$27,624
XifaxanRifaximin11$24,363
LinzessLinaclotide39$20,122
RexultiBrexpiprazole17$19,930
Atorvastatin Calcium1,055$15,774
Spiriva RespimatTiotropium Bromide28$15,621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$71$60,10561 claims
AstraZenecaFarxiga, Breztri Aerosphere$121$39,86386 claims
Otsuka America Pharmaceutical, Inc.Rexulti$125$19,93017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →